Enhancing medication adherence in patients with bipolar disorder

Berk, Lesley; Hallam, K; Colom, Francesc; Vieta, Eduard; Hasty, Melissa K.; Macneil, Craig A.; Berk, Michael

doi:10.1002/hup.1081

Cited by 125 publications

(131 citation statements)

References 93 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…Concordance between clinician and patient views of illness and treatment is a crucial determinant of adherence,339 and reinforces the need for a collaborative approach to the treatment alliance 340. Asking about adherence behaviour and attitudes in a non‐judgemental manner and exploring the reasoning behind poor adherence are important parts of treatment,341 as up to half of patients do not take their medications as prescribed 342, 343, 344.…”

Section: Maintenance Therapy For Bipolar Disordermentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

Self Cite

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Maintenance Therapy For Bipolar Disordermentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…8 Not surprisingly, individuals who report multiple adverse effects are less likely to be adherent, and additional factors such as stigma and acceptance of the illness are important to bear in mind. 12 The need to take medication when symptom-free is a key concern. This viewpoint often reflects a degree of denial by the patient because they are feeling better.…”

Section: Adherencementioning

confidence: 99%

Safe and effective use of lithium

Malhi¹,

Tanious²,

Bargh³

et al. 2013

Aust Prescr

Self Cite

View full text Add to dashboard Cite

“…Given the importance of social inclusion to recovery in BD, as well as the role of stigma in reducing treatment seeking and adherence (Berk et al, 2010;N. Rusch, Corrigan, Wassel, et al, 2009), a more effective investment in treatment may involve a distribution of resources that extends to both sides of the psychosocial equation.…”

Section: Predictors Of Psychosocial Functioning In Bdmentioning

confidence: 99%